Quoin Pharmaceuticals, Ltd. — Director's Dealing 2024

Sep 5, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2024-09-03

Reporting Person: Carter Denise P. (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-03	Ordinary Shares	P	1822	$.6253	Acquired	11179	Direct
2024-09-03	Ordinary Shares	P	4100	$.6551	Acquired	15279	Direct
2024-09-04	Ordinary Shares	P	8825	$.7481	Acquired	24104	Direct
2024-09-04	Ordinary Shares	P	22988	$.7965	Acquired	47092	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.

F2: Effective July 18, 2023, the ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. Effective November 8, 2023, the Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. The amount of ordinary shares reported in this column includes ordinary shares previously included in the Reporting Person's Form 3, adjusted to reflect the number of ordinary shares resulting from the 1 for 60,000 reverse split effective November 8, 2023.